This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Should You Bet on HOLX Stock This Breast Cancer Awareness Month?
by Moumi Mondal
Hologic has kicked off the annual breast cancer awareness month with a new campaign. But how well is the stock doing now?
Reasons to Retain QIAGEN Stock in Your Portfolio for Now
by Zacks Equity Research
Investors feel optimistic about QGEN's strong growth prospects in the NGS platforms. Yet, an unfavorable currency impact on the company's operations is cornering.
QIAGEN Launches QIAcuityDx Digital PCR System: Stock to Gain?
by Zacks Equity Research
QGEN expands its digital PCR portfolio with the newly launched QIAcuityDx Digital PCR System. The system will be used for clinical testing in oncology across North America and Europe.
QGEN Stock to Gain From New IVDR Win for QIAstat-Dx Systems and Panels
by Zacks Equity Research
QIAGEN receives European IVDR certification for QIAstat-Dx syndromic testing instruments and assays.
QIAGEN Stock Likely to Gain From PreAnalytiX's Newly Launched PAXgene
by Zacks Equity Research
PreAnalytiX, a joint venture of QGEN and BD, introduces the PAXgene Urine Liquid Biopsy Set. QGEN will commercialize the latest set.
QGEN Stock Might Rise on Partnership With Bode for GEDmatch PRO
by Zacks Equity Research
QIAGEN announces exclusive global commercial partnership with Bode Technology. Per the agreement, Bode will manage all commercial transactions for QIAGEN's GEDmatch PRO globally.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
QGEN Stock Likely to Gain From Newly Launched Assays for QIAcuity
by Zacks Equity Research
QIAGEN launches 100 new assays for QIAcuity. The newly launched assays are now available through the company???s GeneGlobe platform.
QGEN Stock Likely to Gain From Innovation Amid Competition
by Zacks Equity Research
To support internal growth, QIAGEN invests heavily in research and development for the menu expansion of its key platforms.
Can QGEN Stock Gain From the Expanded Bio-Manguinhos/Fiocruz Alliance?
by Zacks Equity Research
QIAGEN and Bio-Manguinhos/Fiocruz team up to enhance malaria and dengue detection in Brazil's national screening programs.
With HOLX Stock Near 52-Week High, Should You Buy More or Play Safe?
by Moumi Mondal
Hologic's business diversification holds strong potential internationally. Also, its discounted valuation makes it attractive from an investment perspective.
QIAGEN Stock Likely to Gain on Collaboration for APOE Genotyping
by Zacks Equity Research
QGEN collaborates with Eli Lilly to develop a QIAstat-Dx IVD panel for APOE genotyping.
Why Is Qiagen (QGEN) Down 0.3% Since Last Earnings Report?
by Zacks Equity Research
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
QIAGEN and AstraZeneca Expand Pact to Develop CDx in Chronic Diseases
by Zacks Equity Research
QGEN's expanded collaboration with AstraZeneca to focus on developing companion diagnostics beyond oncology.
Reasons to Retain QIAGEN Stock in Your Portfolio Now
by Zacks Equity Research
Investors remain optimistic about QGEN due to its progress in test menu expansion and impressive prospects within its molecular diagnostics segments.
Why Qiagen (QGEN) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Quest Diagnostics' (DGX) New Study Exposes Alarming Data on STI
by Zacks Equity Research
Quest Diagnostics' (DGX) joint study with the University of Alabama finds pregnant women undertested for STIs, raising serious concerns on maternal and newborn health.
Hologic (HOLX) Q3 Results Review: How to Play the Stock Now?
by Moumi Mondal
Hologic's (HOLX) performance in the third quarter of fiscal 2024 marks a return to growth, along with revenues and earnings beating estimates. Read on to find out what else the stock holds.
Here's Why Qiagen (QGEN) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Unlocking Qiagen (QGEN) International Revenues: Trends, Surprises, and Prospects
by Zacks Equity Research
Evaluate Qiagen's (QGEN) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
QIAGEN (QGEN) Q2 Earnings Surpass Estimates, Margins Crash
by Zacks Equity Research
QIAGEN's (QGEN) earnings and revenues beat estimates in the second quarter. The company remains bullish on solid growth trends in the core business.
Compared to Estimates, Qiagen (QGEN) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Qiagen (QGEN) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Qiagen (QGEN) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Qiagen (QGEN) delivered earnings and revenue surprises of 5.77% and 0.45%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's How Zimmer Biomet (ZBH) is Poised Ahead of Q2 Earnings
by Zacks Equity Research
Zimmer Biomet (ZBH) is expected to have witnessed procedure volume recovery banking on strategic product launches in the second quarter.
Ultragenyx (RARE) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Ultragenyx (RARE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.